8.61
+0.02(+0.23%)
Currency In USD
| Previous Close | 8.59 |
| Open | 8.61 |
| Day High | 8.61 |
| Day Low | 8.61 |
| 52-Week High | 16.11 |
| 52-Week Low | 3.55 |
| Volume | 760,675 |
| Average Volume | 905,066 |
| Market Cap | 391.22M |
| PE | -17.22 |
| EPS | -0.5 |
| Moving Average 50 Days | 6.84 |
| Moving Average 200 Days | 6.12 |
| Change | 0.02 |
If you invested $1000 in Y-mAbs Therapeutics, Inc. (YMAB) since IPO date, it would be worth $358.75 as of September 29, 2025 at a share price of $8.61. Whereas If you bought $1000 worth of Y-mAbs Therapeutics, Inc. (YMAB) shares 5 years ago, it would be worth $212.59 as of September 29, 2025 at a share price of $8.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025
GlobeNewswire Inc.
Aug 07, 2025 11:30 AM GMT
PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics fo
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
GlobeNewswire Inc.
Aug 05, 2025 12:30 PM GMT
Acquisition to Include DANYELZA® (Naxitamab-gqgk), Further Broadening SERB’s Rare Oncology Product PortfolioTransaction Expands SERB’s Investment in the U.S.SERB to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Y-mAbs for $8.60
Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline
GlobeNewswire Inc.
May 28, 2025 10:35 AM GMT
Company’s Part A data readout from first-in-human Phase 1 Trial 1001 in patients with recurrent or refractory metastatic solid tumors known to express GD2, validates GD2-SADA as safe, tolerable and able to achieve targeted in vivo conjugation of 177L
Data not available